Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for people living with rare metabolic diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data; gene therapies for Fabry and Pompe diseases, as well as for various types of Batten diseases; enzyme replacement therapies for Pompe diseases; and CDKL5 deficiency disorder product candidates. The company also has additional gene therapies in active preclinical development, including gene therapies for mucopolysaccharidosis type IIIB, as well as a next generation program in mucopolysaccharidosis type IIIA. The company has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.
IPO Year: 2007
Exchange: NASDAQ
Website: amicusrx.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/13/2024 | $17.00 → $12.00 | Overweight → Equal-Weight | Morgan Stanley |
| 9/6/2024 | $18.00 | Buy | Jefferies |
| 5/30/2024 | $18.00 | Overweight | Wells Fargo |
| 5/14/2024 | $13.00 | Neutral → Buy | Guggenheim |
| 12/19/2023 | $15.00 → $20.00 | Equal-Weight → Overweight | Morgan Stanley |
| 9/9/2022 | $14.00 | Equal-Weight | Morgan Stanley |
| 4/13/2022 | $11.00 | Neutral | Goldman |
| 2/24/2022 | $16.00 → $14.00 | Outperform | SVB Leerink |
| 1/14/2022 | $12.00 → $16.00 | Market Perform → Outperform | SVB Leerink |
| 1/13/2022 | $16.00 → $15.00 | Overweight | Cantor Fitzgerald |
2024 Total Revenue of $528.3M, a 33% Increase Year-over-Year Projecting 2025 Total Revenue Growth of 17-24% at CER Anticipate Achieving Positive GAAP Net Income During H2 2025 Conference Call and Webcast Today at 8:30 a.m. ET PRINCETON, N.J., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, today announced financial results for the full-year ended December 31, 2024. "We closed 2024 beating expectations with exceptional revenue growth of 33 percent. With our portfolio and global rare disease capabilities, we have a clear path to deliver cont
PRINCETON, N.J., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD) today announced that the Company will host a conference call and live audio webcast on Wednesday, February 19, 2025, at 8:30 a.m. ET to discuss financial results for the full-year ended December 31, 2024. Participants and investors interested in accessing the call by phone will need to register using the online registration form. After registering, all phone participants will receive a dial-in number along with a personal PIN to access the event. A live audio webcast and related presentation materials can also be accessed via the Investors section of the Amicus Therapeutics corporate website at ir.amicu
PRINCETON, N.J., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD), today announced that two oral presentations and 20 posters across its development programs will be included at the 21st Annual WORLDSymposium™ 2025, being held February 3-7, 2025 in San Diego, CA. "As part of our ongoing efforts to advance our scientific leadership in Fabry and Pompe diseases, Amicus researchers will present two oral presentations and 20 posters at this year's WORLDSymposium," said Bradley Campbell, President and Chief Executive Officer of Amicus Therapeutics, Inc. "We're proud of the progress we are making for patients living with Fabry and Pompe and are committed to build on this momen
2024 Total Revenue of $528M, Representing Significant Growth of 32% Year-Over-Year1 Strong and Growing Demand for Galafold® and Pombiliti® + Opfolda® Total Revenue Growth of 17-24% at CER Expected in 2025 >3,000 People Treated with an Amicus Therapy Today2 PRINCETON, N.J., Jan. 12, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, today provided its preliminary and unaudited 2024 revenue, corporate updates, and full-year 2025 outlook. Bradley Campbell, President and Chief Executive Officer of Amicus Therapeutics, Inc., said, "For Amicus, 20
PRINCETON, N.J., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD) today announced that Bradley Campbell, President and Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Monday, January 13, 2025, at 3:00 p.m. PT. A live audio webcast of the presentation can also be accessed via the investors section of the Amicus Therapeutics corporate website at https://ir.amicusrx.com/events-and-presentations. About Amicus Therapeutics Amicus Therapeutics (NASDAQ:FOLD) is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with
Q3 2024 Total Revenue of $141.5M, a 37% Increase Year-over-Year Galafold® Q3 Revenue of $120.4M, up 20% Year-over-Year Pombiliti® + Opfolda® Q3 Revenue of $21.1M, up 33% from Q2 2024 Raising 2024 Total Revenue Growth Guidance to 30%-32% at CER Reducing non-GAAP Operating Expense Guidance to $340M to $350M Conference Call and Webcast Today at 8:30 a.m. ET PRINCETON, N.J., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, today announced financial results for the third quarter ended September 30, 2024. "The third quarter of the year was marke
PRINCETON, N.J., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD) today announced that management will participate in upcoming presentations at the following investor conferences in November. Guggenheim Healthcare Innovation Conference in Boston, MA, on Tuesday, November 12, 2024, at 2:30 p.m. ETJefferies London Healthcare Conference in London, U.K. on Tuesday, November 19, 2024, at 8:00 a.m. GMT A live audio webcast of each presentation can also be accessed via the investors section of the Amicus Therapeutics corporate website at https://ir.amicusrx.com/events-and-presentations. Additionally, management will attend the J.P. Morgan Equity Opportunities Forum on Wednes
PRINCETON, N.J., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD) today announced that the Company will host a conference call and live audio webcast on Wednesday, November 6, 2024, at 8:30 a.m. ET to discuss financial results for the third quarter ended September 30, 2024. Participants and investors interested in accessing the call by phone will need to register using the online registration form. After registering, all phone participants will receive a dial-in number along with a personal PIN to access the event. A live audio webcast and related presentation materials can also be accessed via the Investors section of the Amicus Therapeutics corporate website at ir.ami
PRINCETON, N.J., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD) today announced that it has entered into a License Agreement (Agreement) with Teva Pharmaceuticals USA, Inc. and Teva Pharmaceuticals, Inc. (collectively Teva). This Agreement resolves the patent litigation brought by Amicus in response to Teva's Abbreviated New Drug Application (ANDA) seeking approval to market a generic version of GALAFOLD® (migalastat) 123mg capsules prior to expiration of the applicable patents. Pursuant to the terms of the Agreement, Amicus will grant Teva a license to market its generic version of GALAFOLD® in the United States beginning on January 30, 2037, if approved by the U.S.
PRINCETON, N.J., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD), today announced that three posters highlighting its development program for Pompe disease will be included at the 29th Annual Congress of the World Muscle Society being held October 8-12, 2024 in Prague, Czechia. Poster Session: Pompe Disease Abstract Title: Cipaglucosidase alfa + miglustat in late-onset Pompe disease: two non-ambulatory patients switching from high-dose, high-frequency alglucosidase alfa (Poster #657P) Presenter: Barry J. Byrne, MD, PhD, University of Florida, Gainesville, FL, U.S.A.Poster Session: Friday, October 11, 3:45 – 4:45 p.m. CETLocation: Forum Hall, The Prague Congress Centr
Daphne Quimi to Retire At Year End PHILADELPHIA, Aug. 21, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, today announced that Simon Harford has been appointed Chief Financial Officer, effective immediately. Simon brings extensive financial leadership experience, having served in significant finance roles in two global pharmaceutical companies as well as most recently as a public company CFO in the biotechnology industry. Daphne Quimi has decided to retire and will remain an Amicus employee through the end of the year to ensure a smooth transition. "Th
PHILADELPHIA, June 14, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD), today announced the election and appointment of Eiry W. Roberts, M.D. to its Board of Directors. Dr. Roberts is an esteemed drug developer who brings approximately 30 years of pharmaceutical industry experience to the Company's Board of Directors, having served in various leadership positions throughout her career and bringing extensive experience advancing therapies across all phases of drug development. John F. Crowley, Chairman and Chief Executive Officer of Amicus Therapeutics, Inc., stated, "On behalf of our Board of Directors, I am pleased to announce the appointment of Dr. Eiry Roberts to the Amicus
Most Recently Served as Global Head of Rare Diseases at Sanofi Genzyme Brings Deep Expertise in Corporate Strategy, Business Development and Commercialization PHILADELPHIA, May 06, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD) today announced the appointment of Sébastien Martel as Senior Vice President of Strategy and Business Development. Mr. Martel will lead the Company's corporate strategy and business and corporate development endeavors. He will be a member of the Amicus senior leadership team. Mr. Martel brings 25 years of diversified pharmaceutical and biotechnology expertise to Amicus, with extensive experience in rare disease, most recently as Senior Vice President
SC 13G/A - AMICUS THERAPEUTICS, INC. (0001178879) (Subject)
SC 13G - AMICUS THERAPEUTICS, INC. (0001178879) (Subject)
SC 13G/A - AMICUS THERAPEUTICS, INC. (0001178879) (Subject)
SC 13G/A - AMICUS THERAPEUTICS, INC. (0001178879) (Subject)
SC 13G/A - AMICUS THERAPEUTICS, INC. (0001178879) (Subject)
SC 13G/A - AMICUS THERAPEUTICS, INC. (0001178879) (Subject)
SC 13G/A - AMICUS THERAPEUTICS, INC. (0001178879) (Subject)
SC 13G/A - AMICUS THERAPEUTICS, INC. (0001178879) (Subject)
SC 13G/A - AMICUS THERAPEUTICS, INC. (0001178879) (Subject)
SC 13G - AMICUS THERAPEUTICS, INC. (0001178879) (Subject)
8-K - AMICUS THERAPEUTICS, INC. (0001178879) (Filer)
424B5 - AMICUS THERAPEUTICS, INC. (0001178879) (Filer)
S-3ASR - AMICUS THERAPEUTICS, INC. (0001178879) (Filer)
144 - AMICUS THERAPEUTICS, INC. (0001178879) (Subject)
10-K - AMICUS THERAPEUTICS, INC. (0001178879) (Filer)
8-K - AMICUS THERAPEUTICS, INC. (0001178879) (Filer)
SCHEDULE 13G/A - AMICUS THERAPEUTICS, INC. (0001178879) (Subject)
8-K - AMICUS THERAPEUTICS, INC. (0001178879) (Filer)
10-Q - AMICUS THERAPEUTICS, INC. (0001178879) (Filer)
8-K - AMICUS THERAPEUTICS, INC. (0001178879) (Filer)
Morgan Stanley downgraded Amicus Therapeutics from Overweight to Equal-Weight and set a new price target of $12.00 from $17.00 previously
Jefferies initiated coverage of Amicus Therapeutics with a rating of Buy and set a new price target of $18.00
Wells Fargo initiated coverage of Amicus Therapeutics with a rating of Overweight and set a new price target of $18.00
Guggenheim upgraded Amicus Therapeutics from Neutral to Buy and set a new price target of $13.00
Morgan Stanley upgraded Amicus Therapeutics from Equal-Weight to Overweight and set a new price target of $20.00 from $15.00 previously
Morgan Stanley initiated coverage of Amicus Therapeutics with a rating of Equal-Weight and set a new price target of $14.00
Goldman resumed coverage of Amicus Therapeutics with a rating of Neutral and set a new price target of $11.00
SVB Leerink reiterated coverage of Amicus Therapeutics with a rating of Outperform and set a new price target of $14.00 from $16.00 previously
SVB Leerink upgraded Amicus Therapeutics from Market Perform to Outperform and set a new price target of $16.00 from $12.00 previously
Cantor Fitzgerald reiterated coverage of Amicus Therapeutics with a rating of Overweight and set a new price target of $15.00 from $16.00 previously
4 - AMICUS THERAPEUTICS, INC. (0001178879) (Issuer)
4 - AMICUS THERAPEUTICS, INC. (0001178879) (Issuer)
4 - AMICUS THERAPEUTICS, INC. (0001178879) (Issuer)
4 - AMICUS THERAPEUTICS, INC. (0001178879) (Issuer)
4 - AMICUS THERAPEUTICS, INC. (0001178879) (Issuer)
4 - AMICUS THERAPEUTICS, INC. (0001178879) (Issuer)
4 - AMICUS THERAPEUTICS, INC. (0001178879) (Issuer)
4 - AMICUS THERAPEUTICS, INC. (0001178879) (Issuer)
4 - AMICUS THERAPEUTICS, INC. (0001178879) (Issuer)
4 - AMICUS THERAPEUTICS, INC. (0001178879) (Issuer)
2024 Total Revenue of $528.3M, a 33% Increase Year-over-Year Projecting 2025 Total Revenue Growth of 17-24% at CER Anticipate Achieving Positive GAAP Net Income During H2 2025 Conference Call and Webcast Today at 8:30 a.m. ET PRINCETON, N.J., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, today announced financial results for the full-year ended December 31, 2024. "We closed 2024 beating expectations with exceptional revenue growth of 33 percent. With our portfolio and global rare disease capabilities, we have a clear path to deliver cont
PRINCETON, N.J., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD) today announced that the Company will host a conference call and live audio webcast on Wednesday, February 19, 2025, at 8:30 a.m. ET to discuss financial results for the full-year ended December 31, 2024. Participants and investors interested in accessing the call by phone will need to register using the online registration form. After registering, all phone participants will receive a dial-in number along with a personal PIN to access the event. A live audio webcast and related presentation materials can also be accessed via the Investors section of the Amicus Therapeutics corporate website at ir.amicu
Q3 2024 Total Revenue of $141.5M, a 37% Increase Year-over-Year Galafold® Q3 Revenue of $120.4M, up 20% Year-over-Year Pombiliti® + Opfolda® Q3 Revenue of $21.1M, up 33% from Q2 2024 Raising 2024 Total Revenue Growth Guidance to 30%-32% at CER Reducing non-GAAP Operating Expense Guidance to $340M to $350M Conference Call and Webcast Today at 8:30 a.m. ET PRINCETON, N.J., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, today announced financial results for the third quarter ended September 30, 2024. "The third quarter of the year was marke
PRINCETON, N.J., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD) today announced that the Company will host a conference call and live audio webcast on Wednesday, November 6, 2024, at 8:30 a.m. ET to discuss financial results for the third quarter ended September 30, 2024. Participants and investors interested in accessing the call by phone will need to register using the online registration form. After registering, all phone participants will receive a dial-in number along with a personal PIN to access the event. A live audio webcast and related presentation materials can also be accessed via the Investors section of the Amicus Therapeutics corporate website at ir.ami
Q2 2024 Total Revenue of $126.7M, a 34% Increase Year-over-Year Galafold® Q2 Revenue of $110.8M, up 17% Year-over-Year Pombiliti® + Opfolda® Q2 Revenue of $15.9M, up 44% from Q1 2024 Raising 2024 Total Revenue Growth Guidance to 26%-31% at CER and 2024 Galafold Growth Guidance to 14%-18% at CER Narrowing non-GAAP Operating Expense Guidance to $345M to $360M Non-GAAP Profitability Achieved in Q2 and H1 2024 with Acceleration Expected in H2 Conference Call and Webcast Today at 8:30 a.m. ET PRINCETON, N.J., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for
PRINCETON, N.J., July 30, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD) today announced that the Company will host a conference call and live audio webcast on Thursday, August 8, 2024, at 8:30 a.m. ET to discuss financial results for the second quarter ended June 30, 2024. Participants and investors interested in accessing the call by phone will need to register using the online registration form. After registering, all phone participants will receive a dial-in number along with a personal PIN to access the event. A live audio webcast and related presentation materials can also be accessed via the Investors section of the Amicus Therapeutics corporate website at ir.amicusrx
1Q 2024 Total Revenue of $110.4M, a 28% Increase Year-over-Year Guiding to Full-Year 2024 Total Revenue Growth of 25%-30% at CER Raising Full-Year 2024 Galafold® Guidance on Continued Strong Demand Strong Pombiliti® + Opfolda® Launch with Increasing Rate of Commercial Patient Starts Reiterating Full-Year Non-GAAP Profitability Projected in 2024 Conference Call and Webcast Today at 8:30 a.m. ET PRINCETON, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, today announced financial results for the first quarter ended March 31, 2024. "Amic
PRINCETON, N.J., May 01, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD) today announced that the Company will host a conference call and live audio webcast on Thursday, May 9, 2024, at 8:30 a.m. ET to discuss financial results for the first quarter ended March 31, 2024. Participants and investors interested in accessing the call by phone will need to register using the online registration form. After registering, all phone participants will receive a dial-in number along with a personal PIN to access the event. A live audio webcast and related presentation materials can also be accessed via the Investors section of the Amicus Therapeutics corporate website at ir.amicusrx.com.
2023 Total Revenue of $399.4M, a 21% Increase Year-over-Year Strong Patient Demand Continues for Pombiliti™ + Opfolda™ in the U.S., U.K., and Germany Projecting 2024 Galafold® Revenue Growth of 11-16% at CER Anticipating Full-Year Non-GAAP Profitability in 2024 Conference Call and Webcast Today at 8:30 a.m. ET PRINCETON, N.J., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, today announced financial results for the full-year ended December 31, 2023. "In 2023, Amicus made tremendous progress across all our strategic priorities," said Bradle
PRINCETON, N.J., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD) today announced that the Company will host a conference call and live audio webcast on Wednesday, February 28, 2024, at 8:30 a.m. ET to discuss financial results for the full-year ended December 31, 2023. Participants and investors interested in accessing the call by phone will need to register using the online registration form. After registering, all phone participants will receive a dial-in number along with a personal PIN to access the event. A live audio webcast and related presentation materials can also be accessed via the Investors section of the Amicus Therapeutics corporate website at ir.amicusr